Aruna Mani

A study to assess the safety and effectiveness of inavolisib plus a cdk4/6 inhibitor and letrozole versus placebo plus a CDK4/6 inhibitor and letrozole in participants with advanced breast cancer

Ezio Corera, Mark Tuthill, Aruna Mani

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

R. Dent, Fabrice André, Anthony Gonçalvès, Miguel Martín et autres

sg, fr, es, gb, de, us, tr, Éthiopie, kr, pr, it, cn, ch, pt, ca (code pays fourni par la source)

Data from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Alena Cristina Jaime‐Ramirez, Elizabeth L. McMichael, SriVidya Kondadasula, Cassandra C. Skinner et autres

Supplemental Figures 1-3 from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Alena Cristina Jaime‐Ramirez, Elizabeth L. McMichael, SriVidya Kondadasula, Cassandra C. Skinner et autres

Data from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Alena Cristina Jaime‐Ramirez, Elizabeth L. McMichael, SriVidya Kondadasula, Cassandra C. Skinner et autres

Supplemental Figures 1-3 from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Alena Cristina Jaime‐Ramirez, Elizabeth L. McMichael, SriVidya Kondadasula, Cassandra C. Skinner et autres

Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Alena Cristina Jaime‐Ramirez, Elizabeth L. McMichael, SriVidya Kondadasula, Cassandra C. Skinner et autres

Supplementary Figure Legends from NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

Alena Cristina Jaime‐Ramirez, Elizabeth L. McMichael, SriVidya Kondadasula, Cassandra C. Skinner et autres

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Nicholas C. Turner, Rebecca Dent, Joyce O’Shaughnessy, Sung‐Bae Kim et autres

gb, sg, us, kr, br, jp, ua, ch, ca, es (code pays fourni par la source)

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

Rebecca Dent, Mafalda Oliveira, Steven J. Isakoff, Seock‐Ah Im et autres

sg, es, us, kr, fr, gb (code pays fourni par la source)

Abstract PS5-06: Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial

Heidi Savage, Wendy Lin, Mafalda Oliveira, Carlos H. Barrios et autres

es, us, gb, sg, jp, ch, kr (code pays fourni par la source)

Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)

Peter Schmid, Delphine Loirat, Peter Savas, Enrique Espinosa et autres

gb, fr, au, es, ca (code pays fourni par la source)